Acumen Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Acumen Pharmaceuticals has a total shareholder equity of $217.2M and total debt of $29.7M, which brings its debt-to-equity ratio to 13.7%. Its total assets and total liabilities are $267.0M and $49.8M respectively.
Key information
13.7%
Debt to equity ratio
US$29.67m
Debt
| Interest coverage ratio | n/a |
| Cash | US$200.34m |
| Equity | US$217.20m |
| Total liabilities | US$49.77m |
| Total assets | US$266.98m |
Recent financial health updates
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Aug 05
Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10Recent updates
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Aug 05Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's
Jul 30Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?
Apr 21Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth
Sep 21We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Feb 01Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 16Acumen Pharma at 11-month high on rivals’ Alzheimer’s data
Sep 28Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate
Jun 30We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth
May 10We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate
Jan 07Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans
Oct 01Financial Position Analysis
Short Term Liabilities: ABOS's short term assets ($207.6M) exceed its short term liabilities ($19.9M).
Long Term Liabilities: ABOS's short term assets ($207.6M) exceed its long term liabilities ($29.9M).
Debt to Equity History and Analysis
Debt Level: ABOS has more cash than its total debt.
Reducing Debt: Insufficient data to determine if ABOS's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ABOS has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ABOS has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 42.9% each year.